PerkinElmer : to Acquire BioLegend

Unlocking Legendary Discovery

PerkinElmer to Combine with BioLegend

July 26, 2021

© 2021 PerkinElmer

SAFE HARBOR

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward- looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the

"Investor Events" section of our website at ir.perkinelmer.com.

2

COMBINATION WITH BIOLEGEND: ACCELERATING LEGENDARY

DISCOVERIES IN PRECISION MEDICINE

• BioLegend is a global provider of high-quality antibodies and reagents
• 2022e revenues of ~$380M with mid-teens+CAGR (excl. synergies) expected going forward
• Purchase price of $5.25B: $2.2B stock consideration with remainder funded by newly issued debt and cash on-hand
• • Committed to remaining investment grade
• Enhanced combined growth and margin profile with $0.30 adj. EPS accretion expected in Year 1 & >$0.50 in Year 2
• • High single-digit adj. ROIC anticipated by Year 6
• Expected to close by year-end2021

Transformative for PerkinElmer life science with additional synergies in diagnostics

3

BIOLEGEND: STRONG INNOVATION DRIVES ATTRACTIVE PROFILE

	BEST-IN-CLASS	~$6B	•	Flow Cytometry
	GLOBAL INNOVATOR	•	Proteogenomics
	of antibodies and	Total Addressable	•	Magnetic Cell Separation
	reagents		•	Immunoassays
		Market*
			~10% Projected Market	•	Recombinant Proteins
	Revenue Split	Growth (2021-2024)	•	Bioprocessing
$380M Revenue2022e
55% North America	COMPETITIVE POSITIONING
100% Recurring Revenue	25%Europe & RoW	• Global provider of innovative antibodies
Accretive Margin Profile	20% Asia Pacific	• Gaining momentum in emerging, high-growth
			areas of proteogenomics, recombinant proteins,
	10K Customers	and bioprocessing
>700	• >1,000 new product introductions annually
Employees	130	Countries	• Expect mid-teens+ organic revenue growth (excl.
synergies)
*Source: External Advisors and Internal Company Estimates

4

STRATEGIC RATIONALE

VALUE CREATION

High-Growth,High-Margin

Markets

Global Reagents

CoE for

Legendary

Discovery

Support PKI Dx

Development

Expands PKI into fast growing, high margin, antibody focused markets. Increases PKI's overall mix of recurring revenue

BioLegend's San Diego HQ will become the content development engine for reagents across the life science portfolio

Leveraging PKI's position in Dx and broad commercial reach will expand impact and accelerate NPIs in high-growthopportunities such as decentralized & multiplex diagnostics

Global Scale

• Reach

Acceleration of

New Product

Introductions

(NPIs)

Further Elevates

Strong

Franchises

• Will create a >$1.5B life science franchise with ~$700M in life science research reagent revenue by 2022e
• Dedicated direct sales teams will drive growth globally, leveraging scale and customer relationships, esp. outside U.S.

Combined expertise and innovation engine will accelerate pace of NPIs in DAS, Dx, and new high-growth areas such as biologics, cell & gene therapy & single cell analysis

The combination will drive powerful brand equity with best-in- class solutions across

respected complementary brands

TARGETING $100M+ OF ANNUALIZED REVENUE SYNERGIES BY YEAR 5

5